P561: Clinical utility of therapeutic drug monitoring of adalimumab using a point of care testECCO'22Year: 2022
Authors: Stevens, T.(1);Teichert, C.(1);Volkers, A.(1);Mostafavi Montazeri, N.(1);Bahur, B.(2);Bray, K.(3);D'Haens, G.(1);
(1)Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)ProciseDx Inc., Clinical Operations, San Diego, United States;(3)ProciseDx Inc., Clinical Development and Medical Affairs, San Diego, United States;
P562: A Phase 1 Study Evaluating the Effect of Coadministration of Etrasimod on the Pharmacokinetics and Pharmacodynamics of a Monophasic Oral Contraceptive in Healthy Female VolunteersECCO'22Year: 2022
Authors: Lee, C.(1);Tang , Y.(1);Villa-Caballero, L.(2);Liu , K.(3);Randle , A.(4);Grundy , J.(1);
(1)Arena Pharmaceuticals- Inc., Nonclinical Dev & Clinical Pharmacology, San Diego, United States;(2)Arena Pharmaceuticals- Inc., Clinical Development, San Diego, United States;(3)Arena Pharmaceuticals- Inc., Biostatistics & Data Mgmt, San Diego, United States;(4)Arena Pharmaceuticals- Inc., Clinical Operations, San Diego, United States;
P563: Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programmeECCO'22Year: 2022
Authors: Rubin, D.T.(1);Torres, J.(2);Regueiro, M.(3);Reinisch, W.(4);Prideaux, L.(5);Kotze, P.G.(6);Tan, F.H.(7);Gardiner, S.(8);Mundayat, R.(8);Cadatal, M.J.(9);Ng, S.(10);
(1)-, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago- IL, United States;(2)Hospital Beatriz Ângelo, Gastroenterology Division, Loures, Portugal;(3)Cleveland Clinic, Department of Gastroenterology- Hepatology and Nutrition, Cleveland- OH, United States;(4)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria;(5)Monash Medical Centre, Department of Gastroenterology and Hepatology, Melbourne- VIC, Australia;(6)Catholic University of Paraná, IBD Outpatient Clinics- Colorectal Surgery Unit, Curitiba, Brazil;(7)-, Pfizer Australia, Melbourne- VIC, Australia;(8)-, Pfizer Inc, New York- NY, United States;(9)-, Pfizer Inc, Manila, Philippines;(10)LKS Institute of Health Science- Chinese University of Hong Kong, Institute of Digestive Disease- Department of Medicine and Therapeutics, Hong Kong, China;
P564: A qualitative exploration of acceptability of long-term use of oral nutritional supplement drinks as partial enteral nutrition in adolescent and adult Crohn's DiseaseECCO'22Year: 2022
Authors: Mu, S.(1);Wei, Y.(1);Weekes, E.(2);Keetarut, K.(2);
(1)University College London, Institute for Liver and Digestive Health- UCL Division of Medicine, London, United Kingdom;(2)University College London Hospital, Nutrition and Dietetics, London, United Kingdom;
P566: Humoral immune response to mRNA COVID-19 vaccine in Puerto Ricans with IBD does not differ between class of biologicsECCO'22Year: 2022
Authors: López Marte, P.(1);Ramos-Tollinchi, L.(1);Rodriguez-Martinó, E.(2);Medina-Prieto, R.(2);Ojeda, S.(3);Santana-Bagur, J.(4);Pantoja, P.(5);Sariol, C.A.(5);Torres, E.A.(2);
(1)University of Puerto Rico-School of Medicine, Gastroenterology Research, San Juan, Puerto Rico;(2)University of Puerto Rico-School of Medicine, Department of Medicine- Division of Gastroenterology, San Juan, Puerto Rico;(3)University of Puerto Rico-School of Medicine, Department of Medicine, San Juan, Puerto Rico;(4)University of Puerto Rico-School of Medicine, Department of Medicine- Division of Infectious Diseases, San Juan, Puerto Rico;(5)University of Puerto Rico-School of Medicine, Department of Microbiology, San Juan, Puerto Rico;
P567: Safety analysis of tofacitinib in ulcerative colitis: Real-world outcomes from a three-year UK observational cohort studyECCO'22Year: 2022
Authors: Honap, S.(1,2);Sharma, E.(1);Ray, S.(1);Mawdsley, J.(1);Anderson, S.(1);Samaan, M.(1);Pavlidis, P.(1,2);Irving, P.(1);
(1)Guy’s and St Thomas’ NHS Foundation Trust, IBD Centre - Department of Gastroenterology, London, United Kingdom;(2)King's College London, School of Immunology and Microbial Sciences, London, United Kingdom;
P568: Impact of Biologics and Small Molecules for Inflammatory Bowel Disease on COVID-19 Related Hospitalization: A Systematic Review and Meta-analysisECCO'22Year: 2022
Authors: Alrashed, F.(1);Alasfour, H.(2);Shehab, M.(3);
(1)Massachusetts College of Pharmacy and Health Sciences MCPHS University, Public health, Boston, United States;(2)Kuwait University, Pharmacy Practice, Aljabreyah, Kuwait;(3)Mubarak Alkaber University Hospital, Internal medicine, Kuwait, Kuwait;
P569: Fecal Microbiome Transplantation for Recurrent C. difficile Colitis: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case SeriesECCO'22Year: 2022
Authors: Urbonas, T.(1,2);Ianiro, G.(3,4);Gedgaudas, R.(1,2);Sabanas, P.(1,2);Urba, M.(1,2);Kiudelis, V.(1,2);Kiudelis, G.(1,2);Petkevicius, V.(1,2);Vitkauskiene, A.(5);Cammarota, G.(3,4);Gasbarrini, A.(3,4);Kupcinskas, J.(1,2);
(1)Lithuanian University of Health Sciences, Department of Gastroenterology, Kaunas, Lithuania;(2)Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania;(3)Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Digestive Disease Center, Rome, Italy;(4)Università Cattolica del Sacro Cuore, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Rome, Italy;(5)Lithuanian University of Health Sciences, Department of Laboratory Medicine, Kaunas, Lithuania;
P570: Prevalence and risk factors for intestinal resection in patients with Crohn’s disease in a Greek referral centerECCO'22Year: 2022
Authors: Orfanoudaki, E.(1);Foteinogiannopoulou, K.(1);Theodoraki, E.(1);Drygiannakis, I.(1);Romanos, I.(2);Koutroubakis, I.E.(1);
(1)University Hospital of Heraklion- Medical School- University of Crete, Gastroenterology, Heraklion, Greece;(2)University Hospital of Heraklion- Medical School- University of Crete, Surgical Oncology, Heraklion, Greece;
P571: The Nordic diet as a tool to improve the activity of disease and psycho-emotional wellbeing in patients with mild and moderate Ulcerative Colitis – the pilot study.ECCO'22Year: 2022
Authors: Birka, I.(1);Girgensone, G.(2);Anspuka, L.(3);Šantare, D.(3);
(1)Paula Stradina Clinical University Hospital, Gastroenterology- hepatology and nutrition, Riga, Latvia;(2)University of Latvia, Faculty of Medicine, Riga, Latvia;(3)University of Latvia, Institute of Clinical and Preventive Medicine, Riga, Latvia;
P572: Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it's time to make iron deficiency part of tight monitoring to reach T2T? – preliminary results of a prospective studyECCO'22Year: 2022
Authors: Molnár, T.(1);Resál, T.(1);Bacsur, P.(1);Rutka, M.(1);Szántó, K.(1);Bálint, A.(1);Milassin, Á.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Farkas, K.(1);
(1)University of Szeged, Department of Medicine- Szent-Györgyi Albert Medical School, Szeged, Hungary;
P573: The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indicationsECCO'22Year: 2022
Authors: Colombel, J.F.(1);Panaccione, R.(2);Nakase, H.(3);Burmester, G.(4);Cohen, S.B.(5);Mease, P.(6);Guttman-Yassky, E.(1);Liu, J.(7);Zhou, W.(7);Ilo, D.(7);Higgins, P.(8);
(1)The Mount Sinai Hospital, Icahn School of Medicine, New York, United States;(2)University of Calgary, Cumming School of Medicine, Alberta, Canada;(3)Sapporo Medical University, Department of Gastroenterology- Rheumatology- and Clinical Immunology, Sapporo, Japan;(4)Charité University Hospital- Free University of Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany;(5)Metroplex Clinical Research Center, Dallas, United States;(6)Swedish Clinical Research, Swedish Rheumatology Research Group, Seattle, United States;(7)AbbVie Inc, Research and Development, North Chicago, United States;(8)University of Michigan, Medical School, Ann Arbor, United States;
P574: Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn‘s diseaseECCO'22Year: 2022
Authors: Suleiman, A.(1);Goebel, A.(1);Bhatnagar, S.(2);D'Cunha, R.(2);Liu, W.(2);Pang, Y.(2);
(1)AbbVie, Clinical Pharmacology & Pharmacometrics, Ludwigshafen, Germany;(2)AbbVie, Clinical Pharmacology & Pharmacometrics, North Chicago, United States;
P575: Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary ResultsECCO'22Year: 2022
Authors: Giordano, A.(1);Rovira, M.(2);Barastegui, R.(1);Marín, P.(2);Martínez, N.(2);Fernández-Aviles, F.(2);Suárez-Lledó, M.(2);Doménech, A.(2);Ordás, I.(1);Fernández-Clotet, A.(1);Caballol, B.(1);Gallego, M.(1);Vara, A.(1);Masamunt, M.C.(1);Giner, A.(1);Corraliza, A.M.(3);Panés, J.(1);Salas, A.(3);Ricart, E.(1);
(1)IDIBAPS. Hospital Clínic, Inflammatory Bowel Disease Unit. Gastroenterology Department., Barcelona, Spain;(2)ICMHO. IDIBAPS. Institut Josep Carreras. Hospital Clínic, BMT Unit- Hematology Department., Barcelona, Spain;(3)Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Inflammatory Bowel Disease Unit, Barcelona, Spain;
P576: Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort studyECCO'22Year: 2022
Authors: Alsoud, D.(1);Franchimont, D.(2);D'Heygere, F.(3);Bossuyt, P.(4);Vijverman, A.(5);Van Hootegem, P.(6);Sabino, J.(1,7);Cremer, A.(2);Vermeire, S.(1,7);Ferrante, M.(1,7);
(1)KU Leuven, Translational Research Center for GastroIntestinal Disorders- Department of Chronic Diseases- Metabolism and Ageing, Leuven, Belgium;(2)Erasme Hospital, Department of Gastroenterology, Brussels, Belgium;(3)AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium;(4)Imelda General Hospital, Imelda GI Clinical Research Centre- Department of Gastroenterology, Bonheiden, Belgium;(5)CHR de la Citadelle, Department of Gastroenterology, Liège, Belgium;(6)AZ Sint-Lucas, Department of Gastroenterology, Brugge, Belgium;(7)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P577: Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel diseaseECCO'22Year: 2022
Authors: Gabriëls, R.Y.(1);Bourgonje, A.R.(1);von Martels, J.(1);Blokzijl, T.(1);Weersma, R.(1);Galinsky, K.(2);Julius, J.(2);Faber, K.N.(1);Kats-Ugurlu, G.(3);Dijkstra, G.(1);
(1)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(2)Takeda Pharmaceutical Company Ltd, Research, Massachusetts, United States;(3)University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, The Netherlands;
P578: Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainabilityECCO'22Year: 2022
Authors: Lontai, L.(1);Gonczi, L.(1);Balogh, F.(1);Komlodi, N.(1);Resal, T.(2);Farkas, K.(2);Molnar, T.(2);Golovics, P.(3);Schafer, E.(3);Szamosi, T.(3);Miheller, P.(4);Ilias, A.(1);LakatosPhD, P.L.(1,5);
(1)Semmelweis University, Department of Medicine and Oncology, Budapest, Hungary;(2)University of Szeged, Department of Medicine, Szeged, Hungary;(3)Hungarian Defence Forces - Medical Centre, Department of Gastroenterology, Budapest, Hungary;(4)Semmelweis University, Department of Surgery and Interventional Gastroenterology, Budapest, Hungary;(5)Mcgill University Health Center, IBD Centre, Montréal, Canada;
P579: Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s diseaseECCO'22Year: 2022
Authors: Derikx, L.(1,2);Plevris, N.(2);Su, S.(2);Gros, B.(2);Lyons, M.(2);Siakavellas, S.(2);Constantine-Cook, N.(3,4);Jenkinson, P.(2);O'Hare, C.(2);Merchant, L.(2);Noble, C.(2);Arnott, I.(2);Jones, G.(2,5);Lees, C.(2,4);
(1)Radboud University Nijmegen Medical Centre, Inflammatory Bowel Disease Centre- Department of Gastroenterology and Hepatology- Route 455, Nijmegen, The Netherlands;(2)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(3)University of Edinburgh, MRC Human Genetics Unit- Institute of Genetics and Molecular Medicine-, Edinburgh, United Kingdom;(4)University of Edinburgh, Centre for Genomics and Experimental Medicine- Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom;(5)University of Edinburgh, Centre for Inflammation Research- The Queen's Medical Research Institute, Edinburgh, United Kingdom;
P580: Early intestinal ultrasound assessment predicts endoscopic response and remission on anti-TNF treatment in Crohn’s Disease – a prospective longitudinal cohort studyECCO'22Year: 2022
Authors: de Voogd, F.(1);Bots, S.(1);Gecse, K.(1);Gilja, O.H.(2);D'Haens, G.(1);Nylund, K.(2);
(1)Amsterdam University Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Haukeland University Hospital, National Centre for Ultrasound in Gastroenterology, Bergen, Norway;
